<DOC>
	<DOCNO>NCT01909388</DOCNO>
	<brief_summary>The Magnetic Resonance ( MR ) provide high resolution soft tissue image allow appropriate assessment local extent disease . Recent study show increase sensitivity specificity detection Dominant intraprostatic lesion use multiparametric MRI diagnostic tool stag disease . Among various irradiation technique currently available prostate cancer , Brachytherapy superior term dose conformation ; conformation allow great dose escalation , adjust isodoses prostate exquisite accuracy , keep healthy adjacent organ , urethra rectum , tolerable dose range Brachytherapy company recently develop software allow TRUS-MR image fusion . The purpose study demonstrate feasibility delivery high prescription dose dominant intra-prostatic nodule define multiparametric MRI . Dose prostate , adjacent structure remain current treatment practice . Timing delivery brachytherapy change current practice</brief_summary>
	<brief_title>Dose Escalation Dominant Intraprostatic Lesions ( DIL ) With MRI-TRUS Fusion High Dose Rate ( HDR ) Prostate Brachytherapy</brief_title>
	<detailed_description>Treatment : The patient 's treatment consist combine Hypofractionated external beam ( 3750 cGray 15 fraction ) MRI-TRUS fusion HDR brachytherapy boost ( 1 fraction 1500 cGray . Brachytherapy perform general anesthesia outpatient procedure TRUS-MRI fusion : T2 axial volumetric sequence ( VISTA ) import directly picture archive communication system ( PACS ) . Then MR image reconstruct segment . Target volume ( prostate gland , dominant intraprostatic lesion ( DILs ) Organs risk ( OARs ) urethra rectum delineate . A transrectal sagittal volumetric ultrasound image immediately adquired every 2 degree , rapid reconstruction algorithm convert series 2D image 3D volume , displayed axial , sagittal coronal view transfer module fusion MRI . The MRI image real-time sonography examination display split-screen possibility overlay image live one image . A graphical user interface use rigid manual registration ultrasound MRI volume . This interface allow displacement three dimension rotation , image correctly superimpose . Then contour structure transfer US dataset , contour slightly modify perfect match US image achieve . Dose prescription : The homogeneity parameter use optimization aim prostate V100 &gt; 98 % , V150 25-33 % , V200 &lt; 8 % , Vn fractional volume organ receive n % prescribe dose , urethral dmax &lt; 115 % rectal 1cc &lt; 70 % prescribe dose . The treatment plan manipulate normally occur high dose region ( 125 % , 150 % ) position site identify disease Endpoints Feasibility high dose administration , toxicity efficacy measure</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men ≥18 year Histologically proven adenocarcinoma prostate Intermediate high risk prostate cancer Intermediate risk prostate cancer patient must : Clinical stage ≤ T2c , Gleason score = 7 iPSA ≤ 20 , Gleason score ≤ 6 iPSA &gt; 10 ≤ 20 . High risk patient may Clinical stage T3 Gleason score 810 PSA &gt; 20 ng/ml A palpable nodule cluster positive biopsy single region suggest presence dominant nodule radiologic correlation MRI . Estimated life expectancy least 10 year . ECOG performance status 0 2 . Signature inform conseny Contraindications interstitial prostate brachytherapy . If coumadin therapy NOT able stop safely 7 day . Does localize high volume intraprostatic disease MRI contraindicate Unfit general anesthetic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>High Dose Rate</keyword>
	<keyword>MRI-TRUS fusion</keyword>
	<keyword>Detection DILs MRI</keyword>
</DOC>